Clinical Trial Update: NADIM II: Neo-Adjuvant Immunotherapy [Phase 2]

View source ↗

Summary

NADIM II is a Phase 2 neoadjuvant immunotherapy trial for non-small cell lung cancer; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fundación GECP | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING